Ocular Immunology and Inflammation最新文献

{"title":"Cytokine Profiling and Clinical Correlates of Conjunctival Wound Healing After Trabeculectomy: Implications for Scar Formation in Glaucoma Patients.","authors":"Qin Zhang, Bo Zhao, Yan Bai","doi":"10.1080/09273948.2025.2516081","DOIUrl":"https://doi.org/10.1080/09273948.2025.2516081","url":null,"abstract":"<p><strong>Purpose: </strong>Understanding the role of scar markers and inflammatory factors in filtering bleb scarring after glaucoma surgery is essential for improving conjunctival wound healing and surgical outcomes. This study aimed to investigate conjunctival wound healing and its impact on scar formation and inflammatory responses in glaucoma patients after surgery.</p><p><strong>Methods: </strong>This study included 130 primary glaucoma patients who underwent trabeculectomy from January 2022 to January 2024. After 4 months of follow-up (with initial assessment at 14 days), patients were categorized into a scarring group (<i>n</i> = 38) and a nonscarring group (<i>n</i> = 92). Scar markers, inflammatory factors, and clinical data were analyzed. Pearson correlation and logistic regression analyses were conducted to explore the factors influencing scarring.</p><p><strong>Results: </strong>Patients in the scarring group had greater preoperative intraocular pressure, lens thickness, and postoperative bleb leakage (<i>p</i> < 0.05). The levels of TGF-β, PDGF, CTGF, IL-6, IL-1β, and IFN-α were significantly greater in the scarring group (<i>p</i> < 0.05). TGF-β, PDGF, and CTGF were positively correlated with IL-6 (<i>p</i> < 0.05) but not with IL-1β or TNF-α (<i>p</i> > 0.05). Logistic regression indicated that bleb leakage and elevated TGF-β, PDGF, CTGF, and IL-6 levels were risk factors for scarring (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>Elevated levels of TGF-β, PDGF, CTGF, and IL-6, along with bleb leakage, are risk factors for filtering bleb scarring after glaucoma surgery.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-10"},"PeriodicalIF":2.6,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human Herpesvirus 6-Associated Unilateral Panuveitis Mimicking Endogenous Endophthalmitis in a Case with Ulcerative Colitis: Report of a Case and Literature Review.","authors":"Omer Karti, Ziya Ayhan, Banu Lebe, Ali Osman Saatci","doi":"10.1080/09273948.2025.2516835","DOIUrl":"https://doi.org/10.1080/09273948.2025.2516835","url":null,"abstract":"<p><strong>Purpose: </strong>To present a rare case of panuveitis caused by Human herpesvirus 6 (HHV-6), initially misdiagnosed as endogenous endophthalmitis.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 41-year-old woman with ulcerative colitis was admitted to us with pain in the right eye. Slit-lamp biomicroscopy of the right eye revealed an ecchymotic and edematous upper eyelid with two papular lesions, diffuse conjunctival hyperemia, severe corneal edema, and dense anterior chamber fibrinous exudation. Left anterior segment was normal. Intraocular pressure was 35 mmHg in the right eye and 15 mmHg in the left eye. Right fundus could not be visualized and B scan ocular ultrasound exhibited an attached retina with dense vitreous echogenicity. A skin biopsy was obtained from the affected eyelid, and vitreous samples were collected via single port dry vitrectomy. As endogenous endophthalmitis could not be ruled out, prophylactic intravitreal vancomycin, ceftazidime, and amphotericin B were administered at the end of the procedure. Following comprehensive clinical evaluation, HHV-6 DNA was detected via PCR analysis of the vitreous sample. The patient was treated with systemic acyclovir, leading to the gradual resolution of the anterior segment inflammation.</p><p><strong>Conclusion: </strong>Present case highlights the importance of including HHV-6 infection in the differential diagnosis of ocular inflammation and emphasizes its ocular features.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-6"},"PeriodicalIF":2.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Non-Infectious Uveitis Macular Edema Using Two Doses of Triamcinolone Acetonide: Comparative Study.","authors":"Carlos Eduardo de Souza, Barbara Zanetti Patricio de Macedo, Monique Viana de Sousa, Lisangela Naomi Morimoto, Luiz H Lima, Cristina Muccioli","doi":"10.1080/09273948.2025.2504580","DOIUrl":"https://doi.org/10.1080/09273948.2025.2504580","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the efficacy and safety of two doses of intravitreal triamcinolone acetonide (2 mg and 4 mg) in treating non-infectious uveitic macular edema.</p><p><strong>Methods: </strong>This prospective, randomized study assigned patients to Group A (4 mg; 0.1 mL) or B (2 mg; 0.05 mL) of intravitreal triamcinolone acetonide. Participants were assessed at 7, 30, 60, and 90 days post-procedure. Central retinal thickness (CRT), best-corrected visual acuity (BCVA), recurrence rate, adverse events (intraocular pressure [IOP] and cataract), and quality-of-life assessment (VFQ-NEI) were analyzed.</p><p><strong>Results: </strong>Thirty-two eyes (16 per group) completed the 3-month follow-up. Group A demonstrated a significantly greater reduction in CRT at the end of follow-up (<i>p</i> = 0.026). Group B had higher recurrence rates (Group A: Four [25%] eyes vs. Group B: eight [50%] eyes; [<i>p</i> = 0.137]). Although both groups showed transient IOP spike at 7 days post-procedure, no cases of intraocular hypertension were noticed at the end of the study. BCVA outcomes were comparable between groups (<i>p</i> = 0.192). The quality-of-life assessment questionnaire revealed significant improvement in near vision (<i>p</i> = 0.031) and mental health (<i>p</i> = 0.021) subscales in Group A.</p><p><strong>Conclusion: </strong>Group A (4 mg) showed better clinical results in terms of anatomic outcomes, recurrence rates, and quality of life measures compared to Group B (2 mg). Although an IOP spike occurred in both groups 1 week post-procedure, no intraocular hypertension was observed 90 days post-procedure. Visual acuity outcomes were comparable between both groups at the end of the follow-up.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Survey of Diagnostic and Management Practices in Retinal Vasculitis: International Uveitis Study Group (IUSG) Retinal Vasculitis Study (ReViSe)-Report 5.","authors":"Renee Liu, Carlos Cifuentes-González, Sapna Gangaputra, Ikhwanuliman Putera, William Rojas-Carabali, Rina La Distia Nora, Alejandra de-la-Torre, Vishali Gupta, James T Rosenbaum, Rupesh Agrawal","doi":"10.1080/09273948.2025.2503337","DOIUrl":"10.1080/09273948.2025.2503337","url":null,"abstract":"<p><strong>Purpose: </strong>Retinal vasculitis (RV) is a complex inflammatory disorder of retinal blood vessels with variability in diagnosis, classification, and management. Despite efforts to standardize definitions, discrepancies persist regarding clinical features, systemic associations, and treatment approaches. This study aimed to assess clinical practices among uveitis specialists to identify areas requiring consensus.</p><p><strong>Methods: </strong>A cross-sectional, semi-structured survey was conducted among members of the International Uveitis Study Group (IUSG). Eligible participants were uveitis specialists with formal training in ocular inflammation. The survey included 120 questions on diagnosis, imaging, systemic associations, and management strategies. Responses were collected anonymously via REDCap (January to August 2024).</p><p><strong>Results: </strong>Fifty-five specialists participated, mainly from Europe, Asia, and North America. Most rated their RV knowledge as \"adequate\" or \"proficient.\" While 85.5% agreed on a definition involving retinal vascular abnormalities with intraocular inflammation, variability persisted in diagnostic and management practices. Diagnostic testing prioritized infectious and systemic causes. Wide-field imaging and fluorescein angiography were commonly used. Methotrexate, mycophenolate, and adalimumab were preferred treatments. Treatment success was primarily defined by improvements in vascular leakage and macular edema. Monitoring practices and referral patterns varied.</p><p><strong>Conclusion: </strong>Substantial variability exists in RV diagnosis and management, highlighting the need for standardized clinical guidelines.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Osteonecrosis in Vogt-Koyanagi-Harada Patients with Varying Cumulative Corticosteroid Dosages in the First 3 Months: A Nationwide Population-Based Cohort Study.","authors":"Chia-Min Wu, Chi-Hsin Hsu, Meng-Yin Lin, Yu-Hsuan Joni Shao, Chia-Li Chang, Fang-Yuan Chang","doi":"10.1080/09273948.2025.2507709","DOIUrl":"https://doi.org/10.1080/09273948.2025.2507709","url":null,"abstract":"<p><strong>Background: </strong>To compare the risk of osteonecrosis (ON) among patients with Vogt-Koyanagi-Harada (VKH) receiving varying cumulative corticosteroid dosages and to evaluate changes in risk over time.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 1,512 patients with VKH in Taiwan's National Health Insurance Research Database from 2000 to 2019. Patients were categorized based on cumulative prednisone-equivalent dosages in the first 3 months of treatment as follows: low dose (<i>n</i> = 544; 0 < dose ≤ 2 g), medium dose (<i>n</i> = 369; 2 < dose ≤ 4 g), high dose (<i>n</i> = 332; > 4 g), and non-users (<i>n</i> = 267; 0 g).</p><p><strong>Results: </strong>Among VKH patients, combined immunotherapy (IMT) was used in 13.1% within 3 months. After adjustments for age, sex, Charlson Comorbidity Index score, disease stage and the IMT use within the first 3 months, the cumulative risk of ON became significant in the fourth and fifth years for both the low-dose group (HR = 4.59, <i>p</i> = 0.047) and the high-dose group (HR = 5.02, <i>p</i> = 0.043).</p><p><strong>Conclusions: </strong>In this study, only 13.1% of VKH patients received combined IMT within the first 3 months, indicating substantial room to increase early IMT utilization. Early use of combination therapy may potentially reduce corticosteroid exposure, lower the risk of ON, and improve visual outcomes. Patients should be informed of the prolonged risk of corticosteroid-induced ON, which can persist for up to four years, to ensure appropriate monitoring and prevention.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenovirus Vasculitis with Necrotising Retinitis and Schisis-Associated Macular Edema (SAME): A Rare Primary Manifestation of HIV-Related Immunodeficiency.","authors":"Sai Bhakti Mishra, Ankush Kawali, Padmamalini Mahendradas, Venkata Ramana Anandula, Rohit Shetty","doi":"10.1080/09273948.2025.2514985","DOIUrl":"https://doi.org/10.1080/09273948.2025.2514985","url":null,"abstract":"<p><strong>Purpose: </strong>Acute retinal necrosis (ARN) is a sight-threatening condition primarily caused by herpesviruses, with adenoviral retinitis being exceedingly rare. We report a case of bilateral adenoviral vasculitis progressing to peripheral necrotizing retinitis in an immunocompromised patient with newly diagnosed HIV, emphasizing the role of polymerase chain reaction (PCR)-based diagnosis and multimodal antiviral therapy.</p><p><strong>Methods: </strong>A 33-year-old male, recently diagnosed with HIV (CD4 count: 158/µL), presented with floaters and blurred vision. Fundus examination revealed bilateral peripheral occlusive vasculitis with blot hemorrhages and macular edema. Anterior chamber fluid analysis via PCR revealed a high viral load of human adenovirus (HAdV) and tested negative for other common viral causes of retinal necrosis. Initial treatment involved topical corticosteroids, intravitreal ganciclovir, and systemic valganciclovir. Due to disease progression, therapy was subsequently escalated to high-dose valacyclovir (2 g TID) with intravitreal ganciclovir and later intravenous cidofovir was introduced.</p><p><strong>Results: </strong>Despite initial worsening, the addition of cidofovir resulted in gradual lesion resolution over 4 weeks, leaving peripheral retinal necrosis. The final best-corrected visual acuity improved to 6/6 (right eye) and 6/8 (left eye), with residual macular ischemia. Concurrent antiretroviral therapy led to immune reconstitution with an increase in CD4 counts to 580/µL. Notably, a distinctive pattern of schisis-associated macular edema (SAME) was observed.</p><p><strong>Conclusion: </strong>Adenoviral necrotizing retinitis remains an underrecognized entity, particularly in immunocompromised patients. This case underscores the importance of PCR testing for HAdV in atypical necrotizing retinitis and highlights the need for a combined treatment approach, including systemic and intravitreal antiviral therapy.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":2.6,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Intravitreal Ganciclovir Injection with or without Oral Valganciclovir versus Topical 2% Ganciclovir for Cytomegalovirus Anterior Segment Infection.","authors":"Chu-Yen Huang, Eugene Yu-Chuan Kang, Yu-Chun Cheng, Yih-Shiou Hwang, Ching-Hsi Hsiao","doi":"10.1080/09273948.2025.2508402","DOIUrl":"https://doi.org/10.1080/09273948.2025.2508402","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the effectiveness of the following two treatment approaches for cytomegalovirus (CMV) anterior segment infection: 1) intravitreal injection of ganciclovir as a loading dose with or without adjunctive oral valganciclovir and 2) topical application of 2% ganciclovir.</p><p><strong>Methods: </strong>We retrospectively reviewed the records of patients diagnosed with CMV anterior segment infection. Patients were categorized into two groups. Group 1 comprised patients who received intravitreal injection of ganciclovir as a loading dose with or without adjunctive oral valganciclovir (<i>n</i> = 48), and group 2 comprised patients who received long-term topical 2% ganciclovir treatment (<i>n</i> = 32). The primary outcome was recurrence-free survival, and the secondary outcomes were changes in intraocular pressure (IOP) and best corrected visual acuity (BCVA).</p><p><strong>Results: </strong>The recurrence rate over the 2-year follow-up was similar in both group 1 and group 2 (35.4% and 34.4%, respectively; <i>p</i> = 1.0). A Kaplan-Meier plot revealed comparable recurrence-free survival (<i>P</i> for log-rank test = 0.958). Both treatment groups exhibited a notable decrease in IOP. BCVA varied over time; however, no differences were observed between the two groups. In group 1, 39 of 48 patients (81.3%) required adjunctive oral valganciclovir, which was taken for a median duration of 55 days.</p><p><strong>Conclusions: </strong>Despite being a short-term treatment, intravitreal injection of ganciclovir as a loading dose with or without additional oral valganciclovir comparably and effectively prevents recurrence relative to the long-term topical application of 2% ganciclovir.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":2.6,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144209056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study.","authors":"Soumyava Basu, Sucheta Ireni, Mudit Tyagi, Thomas H Dohlman, Eleftherios I Paschalis","doi":"10.1080/09273948.2025.2512170","DOIUrl":"https://doi.org/10.1080/09273948.2025.2512170","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with non-infectious uveitis (NIU), refractory to conventional immunomodulatory therapy (IMT).</p><p><strong>Methods: </strong>Prospective, noncomparative, interventional case series. Five patients with bilateral panuveitis (four post-therapeutic vitrectomy) and persistent intraocular inflammation on conventional IMT for > 2 years received three doses of subconjunctival adalimumab 5 mg/0.1 mL at two-week intervals and followed up for 24 weeks.</p><p><strong>Results: </strong>No cases of persistent conjunctival congestion, corneal erosions or infection, or intraocular pressure > 21 mmHg were noted. Improvement in inflammatory scores and best-corrected visual acuity (BCVA) were noted in three patients each and worsening in none. None of the three patients who showed initial improvement in visual acuity had any baseline cystoid macular edema or vitreous haze to account for the improvement in BCVA.</p><p><strong>Conclusion: </strong>Subconjunctival administration of 5 mg adalimumab is a safe and effective therapy for NIU refractory to conventional IMT.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-3"},"PeriodicalIF":2.6,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular and Periocular Leprosy Confirmed by Polymerase Chain Reaction and Histopathology with Therapeutic Insights.","authors":"Smitha Kuthyar Shambu, Kavya Nagaraj, Santosh Ramesh, Nashra Alma, Shruthi Mysore Krishna, Madhusmita Das","doi":"10.1080/09273948.2025.2509719","DOIUrl":"https://doi.org/10.1080/09273948.2025.2509719","url":null,"abstract":"<p><strong>Purpose: </strong>Mycobacterium leprae commonly affects organs such as skin, peripheral nerves, joints and eyes. However, its intraocular presence has not been documented before. Through our retrospective case report, we aim to raise the awareness of the possibility of intraocular invasion by Mycobacterium leprae.</p><p><strong>Methods: </strong>A 56-year-old male, diagnosed with left periocular leprosy at our medical centre, developed pain, redness, and diminution of vision while still on Multi-Drug Therapy (MDT). On examination, he had corneal ulceration, corneal melt, and endophthalmitis. He underwent emergent therapeutic keratoplasty with lateral tarsorrhaphy and multiple intravitreal injections.</p><p><strong>Results: </strong>Histopathological examination of cornea using Ziehl-Neelsen and Fite-Faraco staining techniques revealed the presence of acid-fast bacilli in the corneal epithelium and anterior stroma. The Descemet's membrane was intact with an adherent endothelial plaque-like hypopyon, which also showed positivity for Lepra bacilli on special stains. The corneal button, hypopyon, and vitreous sample tested positive for Mycobacterium leprae detected via polymerase-chain reaction (PCR). He was started on topical fortified imipenem drops & intravitreal Vancomycin + Imipenem + Dexamethasone. USG-B scan after 48 h showed marked improvement with a few moderate dot echoes. Intravitreal injections were repeated every 48 h for 2 weeks, with serial USG B scans showing significant reduction in vitreous echoes.</p><p><strong>Conclusion: </strong>This case report thus provides evidence that Mycobacterium leprae can indeed penetrate the ocular coats despite a good immune response & Multi-Drug Therapy. Intravitreal injection Imipenem seems to be an effective drug choice in the management of Mycobacterium leprae endophthalmitis.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-6"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144136044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual Function and Intraocular Pressure Outcomes Following Surgical Intervention in Pediatric Patients with Inflammatory Glaucoma.","authors":"Abhiram R Manda, Xiangyu Ji, Jordan Comstock, Stephen J Kim, Qingxia Chen, Karen Joos, Sapna S Gangaputra","doi":"10.1080/09273948.2025.2508408","DOIUrl":"https://doi.org/10.1080/09273948.2025.2508408","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates the outcomes of pediatric uveitic glaucoma eyes that received surgery compared to non-surgical pediatric uveitis eyes.</p><p><strong>Methods: </strong>A retrospective chart review was performed of patients diagnosed with inflammatory glaucoma before the age of 18 years. Outcomes, including intraocular pressure (IOP), visual acuity (VA), and inflammatory activity were assessed over two years.</p><p><strong>Results: </strong>Thirty-six eyes (18 surgically managed, 18 non-surgical) were included in this study. At baseline the surgical eyes had significantly higher median IOP than the non-surgical pediatric uveitis eyes (31.5 mmHg versus 15.0 mmHg; <i>p</i> < 0.001). Two years later, the median IOP between the surgical eyes and non-surgical eyes was not significantly different (12.0 mmHg versus 13.5 mmHg; <i>p</i> = 0.14). Median visual acuity (VA) was not significantly different between surgically managed eyes (logMAR 0.35 [IQR: 0.10-0.50] and non-surgical eyes 0.10 [IQR: 0.03-0.85]; <i>p</i> = 0.92) at baseline. At two years, the median VA in surgical eyes improved to 0.30 (IQR: 0.12-0.70), while the non-surgical eyes maintained a stable median VA of 0.10 (IQR: 0.00-0.20). The mean number of glaucoma medications in the surgical eyes decreased considerably from 3.2 ± 1.6 medications at baseline to 0.67 ± 1.1 at two years.</p><p><strong>Conclusion: </strong>Our data showcases that glaucoma surgery in patients with well controlled uveitis, can provide significant benefit to patients that are refractory to medical management, by reducing IOP and glaucoma medication burden, with excellent visual outcomes at two years.</p>","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":2.6,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}